7RQQ image
Entry Detail
PDB ID:
7RQQ
Keywords:
Title:
Structure of chimeric antibody F10heavy_L9light with PfCSP peptide NANPNVDP
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2021-08-06
Release Date:
2022-03-02
Method Details:
Experimental Method:
Resolution:
1.89 Å
R-Value Free:
0.20
R-Value Work:
0.16
R-Value Observed:
0.16
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:F10 Heavy Chain
Chain IDs:A (auth: H)
Chain Length:227
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:L9 Kappa Chain
Chain IDs:B (auth: L)
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:PfCSP peptide NANPNVDP
Chain IDs:C (auth: P)
Chain Length:8
Number of Molecules:1
Biological Source:Plasmodium falciparum 3D7
Primary Citation
The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria.
Cell Rep 38 110367 110367 (2022)
PMID: 35172158 DOI: 10.1016/j.celrep.2022.110367

Abstact

L9 is a potent human monoclonal antibody (mAb) that preferentially binds two adjacent NVDP minor repeats and cross-reacts with NANP major repeats of the Plasmodium falciparum circumsporozoite protein (PfCSP) on malaria-infective sporozoites. Understanding this mAb's ontogeny and mechanisms of binding PfCSP will facilitate vaccine development. Here, we isolate mAbs clonally related to L9 and show that this B cell lineage has baseline NVDP affinity and evolves to acquire NANP reactivity. Pairing the L9 kappa light chain (L9κ) with clonally related heavy chains results in chimeric mAbs that cross-link two NVDPs, cross-react with NANP, and more potently neutralize sporozoites in vivo compared with their original light chain. Structural analyses reveal that the chimeric mAbs bound minor repeats in a type-1 β-turn seen in other repeat-specific antibodies. These data highlight the importance of L9κ in binding NVDP on PfCSP to neutralize sporozoites and suggest that PfCSP-based immunogens might be improved by presenting ≥2 NVDPs.

Legend

Protein

Chemical

Disease

Primary Citation of related structures